William Robinson

William Robinson, DPT, Ph.D. serves as a Professor in the Biomedical Education and Data Science department at the Lewis Katz School of Medicine, Temple University. His academic journey includes a PhD in Anatomy from Penn State University College of Medicine, a DPT in Physical Therapy, and a BS in Biology, both from Belmont University.

• PhD, Anatomy, Penn State University, College of Medicine, Hershey, PA
• DPT, Physical Therapy, Belmont University, Nashville, TN
• BS, Biology, Belmont University, Nashville, TN

Dr. Robinson's research spans multiple disciplines with primary interests in Anatomy, Ophthalmology, and Musculoskeletal Wellness. His scholarly contributions demonstrate an evolution from early work in neuropharmacology and opioid research to more recent focus on cancer immunotherapy and clinical trials for rare tumors. He maintains active membership in the American Association of Anatomists, reflecting his commitment to anatomical sciences.

Analysis of Dr. Robinson's publication record reveals a significant shift in research focus over time. His recent publications (2024-2025) primarily address cancer immunotherapy, particularly dual anti-CTLA-4/PD-1 blockade in rare tumors and ovarian cancer, while his earlier work (2007-2008) focused on neuropharmacology, examining interactions between beta-lactam antibiotics and opioid receptors in animal models.

• American Association of Anatomists

Dr. Robinson has been actively involved in major clinical research initiatives, including the SWOG/NCI Phase II trials investigating immunotherapy approaches for rare cancers. His work bridges basic science and clinical applications, with recent contributions to understanding durable responses and pseudoprogression in small cell carcinoma of the ovary. While specific grant information isn't provided in the available materials, his participation in large-scale clinical trials suggests significant research funding support.

Dr. Robinson's laboratory and research team appear to focus on translational research, moving from basic pharmacological investigations to clinical applications in oncology. His work with the DART SWOG S1609 trial indicates collaboration with multi-institutional research teams focused on advancing treatment options for rare tumor types.